Xconomy

12/01/2020

Get it right the first time. You're a pioneer on the right path forward.

Biopharmaceutical start-ups need to navigate the complex path to commercialization. The combination of an extensive product and services portfolios with expert support and knowledge will allow you: rise above risks, accelerate drug development, and navigate the path to commercialization.

Learn more: https://youtu.be/w8VQQY7XhFc?utm_source=Informa%20Xconomy&utm_medium=EB%20Pathways%20Video&utm_campaign=EB%20Pathways

10/08/2020

Eventually most product distribution and patient access programs experience service disruptions, face unforeseen challenges, and receive negative feedback from stakeholders. Why? Download this whitepaper to learn more.

A guide to performing check-ups on pharmaceutical distribution and patient access programs

10/06/2020

Xconomy Insight's latest whitepaper is ready for download: Learn how a patient-centric, tech-driven approach can broaden access to research/reach patients regardless of geography, ethnicity, s*x, or gender.

How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, s*x, or gender

10/02/2020

Solid Biosciences has answered the FDA’s outstanding questions about its Duchenne muscular gene therapy, clearing a clinical trial to now resume after patient complications last year led the agency to halt the study for a second time.

Solid Biosciences has answered the FDA’s outstanding questions about its Duchenne muscular gene therapy, clearing a clinical trial to now resume after

10/01/2020

The announcement after the market close on Wednesday follows the May failure of the drug, elafibranor, in a pivotal NASH study.

Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis (NASH) and implementing a corporate restructuring

09/30/2020

“We’ll now definitely move it forward in Dravet and have the discussion with the FDA in Lennox-Gastaut ... And with the results in CDKL5 and Dup15q, we believe there is a route forward.”

Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is

09/29/2020

Praxis is developing drugs intended to address the misfiring neuronal circuitry at the root of some neurological disorders.

Praxis Precision Medicines kept mostly quiet about its research on central nervous system disorder (CNS) drugs until May, when it emerged from stealth and

09/25/2020

Combined Therapeutics Inc Therapeutics Wins $250,000 MilliporeSigma Advance Biotech Grant: https://xconomy.com/national/2020/09/25/combined-therapeutics-wins-250000-milliporesigma-advance-biotech-grant/

09/24/2020

The best in biotech.

Congratulations to all the finalists and winners! This year we received over 600 nominations across 10 award categories. Each nomination was carefully

09/24/2020

Registration is still open for today's National Xconomy Awards! Sign up now for free and watch the live webcast at 3pm ET + network with 700 life science leaders. Help us celebrate the best in biotech: https://xconomy.bioprocessintl.com/national-xconomy-awards-registration-2020

09/23/2020

“We hope to slow down the disease progression, but we do believe our approach has the ability to show improvement,” in cognition and other measures, Kawas says.

The key to Athira Pharma’s approach to Alzheimer’s disease is already inside each of us: a repair mechanism that can regenerate damaged neurons. What’s

09/22/2020

Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be considered sufficiently different for purposes of awarding orphan drug designation or exclusivity.

Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be

09/18/2020

Next week, Diversity and Inclusion in Biotech will bring the life science community together for an afternoon of dynamic discussions with practical solutions for incorporating all dimensions of diversity and inclusion throughout your organization.



This two-part program commences with a leadership panel sharing honest insight into challenges they faced with their diversity and inclusion programs, what worked, what didn’t work, and how to implement change.

The second will be more interactive with 12 moderator-led roundtable discussions on topics ranging from “When Do You Call Out Lack of Diversity and Inclusion?” to “Building Leadership and Development Opportunities for Women in Life Sciences.”

https://informaconnect.com/diversity-inclusion/?utm_source=LinkedIn&utm_medium=post&utm_campaign=Colleagues

09/16/2020

Join us next Monday at Xcelerate at Biotech Week Boston to hear Moderna CMO Tal Zaks discuss the latest on the COVID-19 vaccine race! The event - focused on innovative solutions during this time of uncertainty - also includes expert sessions on regulatory guidance, pipeline management, clinical trial recruitment, incorporating diversity, safety and efficacy, and more.
https://xconomy.com/boston/2020/09/16/moderna-cmo-talks-covid-19-vaccine-at-xcelerate-next-week/

09/15/2020

The deal is a vote of confidence in SeaGen’s technology.

Seattle Genetics is in line to receive $1.72 billion from Merck via a pair of deals, one for a cancer drug that’s still in development and the other for

09/14/2020

The Gilead Sciences acquisition announced Sunday comes five months after Immunomedics won FDA approval for cancer drug sacitizumab govitecan (Trodelvy).

Gilead Sciences is acquiring Immunomedics in a $21 billion deal, the latest in a string of transactions the company has made to bolster its cancer drug

09/14/2020

Petri is hosting its first virtual summit, The Dish: A celebration of bio + engineering, on Sept. 16 from 12-2:30 PM EST. Hear from experts in the field, meet Petri's portfolio companies, and network with others in the space.
https://www.petri.bio/thedish

09/11/2020

The rules defining how a protein is made and what it does in the body are set out by Mother Nature, says Geoff von Maltzhan, Generate’s co-CEO. Generate’s technology aims to decipher those rules by analyzing “every known protein on every branch of the tree of life.”

When biotech startups emerge from stealth, executives typically talk about new molecules in the pipeline and novel approaches they take to treating a